Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:55:50 EST Tue 17 Nov 2026
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR+ Search
SEDAR+ Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR+ Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login ID:
Password:
Save
Q:MBRX
- MOLECULIN BIOTECH INC -
https://moleculin.com
17:55:50 EST
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
MBRX
- Q
0.1
5.77
·
9.94
0.1
6.83
-0.31
-4.3
12.0
71
459
7.50
7.50
6.81
228.50 3.228
16:10:05
Nov 16
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Financial Status:
Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Portfolio
Recent Trades - Last 10 of 459
More trades...
Time ET
Ex
Price
Change
Volume
16:10:05
Q
6.98
-0.16
1
16:10:04
Q
6.98
-0.16
1
16:10:04
Q
6.98
-0.16
1
16:04:01
Q
6.98
-0.16
1
16:04:01
Q
6.98
-0.16
1
16:04:00
Q
6.98
-0.16
1
16:04:00
Q
6.98
-0.16
1
16:02:35
Q
7.11
-0.03
20
16:00:11
Q
6.98
-0.16
1
16:00:11
Q
6.98
-0.16
1
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2026-11-16 07:30
U:MBRX
News Release
200
Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
2026-11-12 08:37
U:MBRX
News Release
200
Moleculin Secures Australian Patent for Annamycin Formulation Technology
2026-11-10 14:45
U:MBRX
News Release
200
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
2026-11-04 11:00
U:MBRX
News Release
200
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-10-30 08:40
U:MBRX
News Release
200
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
2026-10-20 08:12
U:MBRX
News Release
200
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
2026-10-16 09:20
U:MBRX
News Release
200
Moleculin Announces Reverse Stock Split
2026-10-07 08:45
U:MBRX
News Release
200
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
2026-09-29 08:45
U:MBRX
News Release
200
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
2026-09-28 07:00
U:MBRX
News Release
200
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
2026-09-25 13:05
U:MBRX
News Release
200
Annamycin Turns "Cold" Pancreatic Tumors "Hot" in New Preclinical Data Presented at AACR
2026-09-23 08:25
U:MBRX
News Release
200
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
2026-09-14 08:35
U:MBRX
News Release
200
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
2026-09-11 08:30
U:MBRX
News Release
200
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
2026-08-27 09:01
U:MBRX
News Release
200
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-14 08:30
U:MBRX
News Release
200
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
2026-07-31 10:12
U:MBRX
News Release
200
Moleculin Announces Pricing of $9.3 Million Public Offering
2026-07-31 08:10
U:MBRX
News Release
200
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
2026-07-06 08:33
U:MBRX
News Release
200
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
2026-06-30 08:30
U:MBRX
News Release
200
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control